Definium Therapeutics (NASDAQ:DFTX) Sees Strong Trading Volume – Should You Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares saw strong trading volume on Monday . 1,217,849 shares were traded during mid-day trading, a decline of 34% from the previous session’s volume of 1,855,422 shares.The stock last traded at $22.89 and had previously closed at $23.55.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Leerink Partners boosted their price target on Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of Definium Therapeutics in a research note on Thursday, April 23rd. HC Wainwright raised their price target on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wolfe Research initiated coverage on shares of Definium Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $25.00 price target on the stock. Finally, Canaccord Genuity Group set a $38.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $37.92.

Definium Therapeutics Trading Down 0.3%

The business has a 50 day simple moving average of $22.02 and a 200-day simple moving average of $17.70. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -9.22 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, equities analysts predict that Definium Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DFTX. Commodore Capital LP increased its position in Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after purchasing an additional 475,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after acquiring an additional 198,878 shares in the last quarter. Rosalind Advisors Inc. lifted its holdings in shares of Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after acquiring an additional 330,000 shares in the last quarter. UBS Group AG lifted its holdings in shares of Definium Therapeutics by 7.3% during the 3rd quarter. UBS Group AG now owns 551,809 shares of the company’s stock valued at $6,506,000 after acquiring an additional 37,364 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of Definium Therapeutics during the 3rd quarter valued at $4,337,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.